NasdaqGS:RXRXBiotechs
Why Recursion (RXRX) Is Up 10.8% After Deepening Citeline Partnership To Power AI-Driven Clinical Trials
In late March 2026, Recursion Pharmaceuticals announced an expanded partnership with Citeline to deepen integration of real-world data into its AI-enabled ClinTech Platform, aiming to improve clinical trial design, site selection, and development decisions across its investigational portfolio.
This move highlights how Recursion is trying to broaden the role of its AI-native platform beyond discovery into more predictive, patient-centered clinical execution, potentially making its technology...